ReviewBreast cancer research and treatment2025
Overview of ocular toxicities associated with breast cancer therapies.
Review in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer remains the most frequently diagnosed malignancy among women worldwide. Advances in treatment with the approval of multiple novel therapeutics have led to significant improvements in long-term survival and reduced mortality. Although clinicians are familiar with the more common toxicities linked to targeted therapies, ocular adverse effects often receive less attention. Increasing provider awareness of these potential eye-related toxicities is essential to ensure prompt recognition and timely referral to ophthalmologists for early intervention.
methodsWe reviewed evidence on the prevalence, characteristics, and management of ocular toxicities associated with novel targeted breast cancer therapies.
conclusionThis review summarizes the major ocular toxicities linked to targeted therapies used in breast cancer and describes current strategies for their effective clinical management.
Indexed as
Identifiers
41364346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.